Molecularly regulated release of angiogenic factors from superporous hydrogels

超孔水凝胶中血管生成因子的分子调控释放

• 批准号: 9276516
• 负责人: Yong Wang
• 金额: $ 42.96万
• 依托单位: PENNSYLVANIA STATE UNIVERSITY, THE
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2020-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9276516
• 关键词: Affinity; Angiogenic Factor; Architecture; Attention; Binding; Biocompatible Materials; Biological Assay; Blood Vessels; Bolus Infusion; Cell Survival; Cells; Chemicals; Chronic; Competitive Binding; Complex; Data; Development; Diabetic wound; Disease; Disease model; Dose; Exhibits; Future; Generations; Growth; Growth Factor; Hybrids; Hydrogels; Implant; In Vitro; Injectable; Injection of therapeutic agent; Investigation; Ischemia; Kinetics; Lead; Link; Localized Disease; Methods; Molecular; Mus; Myocardial Infarction; Nucleic Acids; Organ; Oxygen; Physical Stimulation; Polymers; Procedures; Process; Property; Site; Specificity; Stroke; Structure-Activity Relationship; System; Technology; Testing; Time; Tissue Engineering; Tissue Survival; Tissues; Transport Process; Ultrasonography; Vascularization; Work; angiogenesis; aptamer; base; cell growth; controlled release; design; dosage; improved; in vivo; injured; novel; novel strategies; nutrition; platelet-derived growth factor BB; public health relevance; release factor; repaired; response; systemic toxicity; therapeutic angiogenesis

 DESCRIPTION: Vascularization is important for the treatment of various ischemic diseases and the survival of tissue-engineered constructs. Thus, the development of angiogenesis strategies has continuously attracted great attention in various fields. However, the realization o successful angiogenesis is challenging, because vascular formation and maturation involve multiple growth factors at different stages. Moreover, while insufficient angiogenic factors do not induce effective angiogenesis, excess angiogenic factors can lead to the formation of defective and leaky blood vessels. Thus, therapeutic angiogenesis requires not only multiple growth factors, but also mechanisms for modulating the time, dosage, and sequential order of growth factor delivery. While bolus injections are the simplest way to control the time, dosage, and sequential order of growth factor delivery, this mode of delivery requires very high levels of growth factors. It can lead to severe systemic toxicity. By contrast, polymeric delivery systems hold great promise for localized delivery of growth factors with reduced systemic toxicity. However, it is challenging to develop a polymeric system to control the release time, dosage and sequential order of multiple growth factors. The objective of this application is to develop a novel molecularly controlled release mechanism and a hydrogel-based polymeric system that can release multiple angiogenic factors with differential and independent timing and dose control, hence regulating angiogenesis in a dynamic manner. The central hypothesis is that multiple growth factors would be sequestered within the same hydrogel by specific binding to hydrogel-linked nucleic acid aptamers, and released specifically by competitive binding of complementary sequence (CS) triggers. To test this hypothesis, we will work on three specific aims: 1) to synthesize aptamer-functionalized superporous hydrogels (AS-gels) for high-capacity sequestration and retention of multiple growth factors; 2) to design and optimize aptamer and CS sequences and to determine molecularly regulated growth factor release from AS-gels in vitro; and 3) to investigate molecularly regulated growth factor release from AS-gels and angiogenesis in mice. We have performed preliminary studies and acquired compelling data showing that AS-gels can sequester growth factors and release them in the presence of CS triggers. More importantly, AS-gels can be triggered to release growth factors to stimulate angiogenesis in vivo. Therefore, the accomplishment of this project will lead to a novel strategy for on-demand delivery of multiple growth factors. It will benefit the treatment of various ischemic diseases such as repair of internal organs where it is too harmful or impossible to repeatedly inject growth factors directly into the tissue.

 产品说明： 血管化对于各种缺血性疾病的治疗和组织工程构建物的存活是重要的。因此，血管生成策略的发展在各个领域不断引起极大的关注。然而，实现成功的血管生成是具有挑战性的，因为血管形成和成熟涉及不同阶段的多种生长因子。此外，虽然血管生成因子不足， 诱导有效的血管生成，过量的血管生成因子可导致缺陷和渗漏血管的形成。因此，治疗性血管生成不仅需要多种生长因子，还需要调节生长因子递送的时间、剂量和顺序的机制。虽然推注是控制生长因子递送的时间、剂量和顺序的最简单方法，但这种递送模式需要非常高水平的生长因子。可导致严重的全身毒性。相比之下，聚合物递送系统对于生长因子的局部递送具有很大的希望，同时降低全身毒性。然而，开发聚合物系统来控制多种生长因子的释放时间、剂量和顺序是具有挑战性的。本申请的目的是开发一种新的分子控制释放机制和一种基于水凝胶的聚合物系统，其可以以不同的和独立的定时和剂量控制释放多种血管生成因子，从而以动态方式调节血管生成。中心假设是多种生长因子将通过与水凝胶连接的核酸适体的特异性结合而被隔离在同一水凝胶内，并通过互补序列（CS）触发物的竞争性结合而特异性释放。为了验证这一假设，我们将从三个方面进行研究：1）合成具有核酸适体功能的超多孔水凝胶（AS-gels），以实现对多种生长因子的高容量隔离和保留; 2）设计和优化核酸适体和CS序列，并在体外测定分子调控的生长因子从AS-gels的释放; 3）研究分子调控的生长因子从AS-凝胶释放和小鼠血管生成。我们已经进行了初步研究，并获得了令人信服的数据，表明AS-凝胶可以螯合生长因子，并在CS触发剂的存在下释放它们。更重要的是，AS-凝胶可以被触发释放生长因子以刺激体内血管生成。因此，该项目的完成将导致一种新的战略，按需交付多种增长因素。它将有益于治疗各种缺血性疾病，如修复内脏器官，其中将生长因子直接重复注射到组织中太有害或不可能。